Pan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cells

BMC Genomics

Volumn 13, Issue 1, 2012, Pages

  Majumdar, Gipsy ^a   Adris, Piyatilake ^a   Bhargava, Neha ^a   Chen, Hao ^b   Raghow, Rajendra ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cardiac gene expression; HDAC inhibitor; Inflammation

Indexed keywords

3 CARBOXYCINNAMIC ACID BIS HYDROXAMIDE; EARLY GROWTH RESPONSE FACTOR 1; GAMMA INTERFERON; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HEART MUSCLE CELL; INFLAMMATION; NONHUMAN; PROMOTER REGION; PROTEIN MOTIF; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; BINDING SITES; CARDIOMEGALY; CELL LINE; CELL PROLIFERATION; CINNAMATES; GENE REGULATORY NETWORKS; GENOMICS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INFLAMMATION; MYOCYTES, CARDIAC; RATS; SIGNAL TRANSDUCTION; SIRTUINS; SOFTWARE; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

MUS;

EID: 84871145557     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-13-709     Document Type: Article

References (57)

1. Martin C, Zhang Y. Mechanisms of epigenetic inheritance. Curr Opin Cell Biol 2007, 19(3):266-272.
2. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705.
3. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007, 128(4):707-719.
4. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008, 31(4):449-461.
5. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008, 9(3):206-218.
6. Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab 2008, 7(2):104-112.
7. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006, 98(1):15-24.
8. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, Olson EN. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Investig 2008, 118(11):3588-3597.
9. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, Turner BM. Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem 2007, 282(7):4408-4416.
10. Potthoff MJ, Olson EN, Bassel-Duby R. Skeletal muscle remodeling. Curr Opin Rheumatol 2007, 19(6):542-549.
11. Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM, Francis J. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010, 56(3):437-444.
12. McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol 2012, 52:303-319.
13. Kee HJ, Kook H. Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 2009, 47(6):770-780.
14. Majumdar G, Johnson IM, Kale S, Raghow R. Epigenetic regulation of cardiac muscle-specific genes in H9c2 cells by Interleukin-18 and histone deacetylase inhibitor m-carboxycinnamic acid bis-hydroxamide. Mol Cell Biochem 2008, 312(1-2):47-60.
15. Stuck BJ, Lenski M, Bohm M, Laufs U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 2008, 283(47):32562-32569.
16. Watkins SJ, Borthwick GM, Arthur HM. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. Vitro Anim Cell Dev Biol 2011, 47(2):125-131.
17. Majumdar G, Rooney RJ, Johnson IM, Raghow R. Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy. Physiol Genomics 2011, 43(24):1319-1333.
18. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6(3):238-243.
19. Barter MJ, Pybus L, Litherland GJ, Rowan AD, Clark IM, Edwards DR, Cawston TE, Young DA. HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol 2010, 29(7):602-612.
20. Chen CS, Weng SC, Tseng PH, Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005, 280(46):38879-38887.
21. Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011, 17(5-6):333-352.
22. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008, 70:23-49.
23. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27(41):5527-5541.
24. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009, 34(3):115-127.
25. Long YC, Glund S, Garcia-Roves PM, Zierath JR. Calcineurin regulates skeletal muscle metabolism via coordinated changes in gene expression. J Biol Chem 2007, 282(3):1607-1614.
26. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007, 26(22):3100-3112.
27. Schieven GL. The p38alpha kinase plays a central role in inflammation. Curr Top Med Chem 2009, 9(11):1038-1048.
28. Ozaki K, Minoda A, Kishikawa F, Kohno M. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochem Biophys Res Commun 2006, 339(4):1171-1177.
29. Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 2002, 3(1):69-75.
30. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132(3):344-362.
31. Smale ST. Hierarchies of NF-kappaB target-gene regulation. Nat Immunol 2011, 12(8):689-694.
32. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem Sci 2008, 33(7):339-349.
33. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007, 34(4):255-262.
34. Strom CC, Aplin M, Ploug T, Christoffersen TE, Langfort J, Viese M, Galbo H, Haunso S, Sheikh SP. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 2005, 272(11):2684-2695.
35. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000, 102(20 Suppl 4):14-23.
36. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006, 21(1):20-23.
37. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
38. Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Curr Pharm Des 2010, 16(3):268-276.
39. McKinsey TA. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011, 17(5-6):434-441.
40. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011, 32(7):335-343.
41. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010, 21(1):49-59.
42. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325(5942):834-840.
43. Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol 2007, 8(4):284-295.
44. Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 2006, 7(6):437-447.
45. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009, 41(1):185-198.
46. Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J, Li H, Xie L, Zhao W, Yao Y, et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 2010, 327(5968):1004-1007.
47. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138(5):1019-1031.
48. Belyi VA, Levine AJ. One billion years of p53/p63/p73 evolution. Proc Natl Acad Sci U S A 2009, 106(42):17609-17610.
49. Ak P, Levine AJ. p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2010, 24(10):3643-3652.
50. Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM, Evstafieva AG. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci U S A 2010, 107(29):12828-12833.
51. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 2010, 107(16):7461-7466.
52. Gonzalez FJ. Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet 2008, 23(1):2-7.
53. Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007, 22(4):287-298.
54. Zhang LX, Zhao Y, Cheng G, Guo TL, Chin YE, Liu PY, Zhao TC. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am J Physiol Heart Circ Physiol 2010, 298(6):H2154-H2163.
55. Hestand MS, van Galen M, Villerius MP, van Ommen GJ, den Dunnen JT, t'Hoen PA. CORE_TF: a user-friendly interface to identify evolutionary conserved transcription factor binding sites in sets of co-regulated genes. BMC Bioinformatics 2008, 9:495.
56. Smirnova IV, Bittel DC, Ravindra R, Jiang H, Andrews GK. Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1. J Biol Chem 2000, 275(13):9377-9384.
57. Majumdar G, Harrington A, Hungerford J, Martinez-Hernandez A, Gerling IC, Raghow R, Solomon S. Insulin dynamically regulates calmodulin gene expression by sequential o-glycosylation and phosphorylation of sp1 and its subcellular compartmentalization in liver cells. J Biol Chem 2006, 281(6):3642-3650.